0.70
+0.0525(+8.07%)
Currency In USD
| Previous Close | 0.65 |
| Open | 0.65 |
| Day High | 0.8 |
| Day Low | 0.65 |
| 52-Week High | 10.2 |
| 52-Week Low | 0.63 |
| Volume | 556,494 |
| Average Volume | 108,720 |
| Market Cap | 1.28M |
| PE | 0 |
| EPS | 164.37 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 1.66 |
| Change | 0.05 |
If you invested $1000 in Bluejay Diagnostics, Inc. (BJDX) since IPO date, it would be worth $0.02 as of January 19, 2026 at a share price of $0.703. Whereas If you bought $1000 worth of Bluejay Diagnostics, Inc. (BJDX) shares 3 years ago, it would be worth $0.19 as of January 19, 2026 at a share price of $0.703.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
GlobeNewswire Inc.
Dec 29, 2025 12:00 PM GMT
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
GlobeNewswire Inc.
Nov 10, 2025 12:30 PM GMT
Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization.Patient enrollment in SYMON-II clinical trial now approximately 50% completed.Recent p
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Oct 10, 2025 9:16 PM GMT
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously